DBV Technologies S.A. Overview
Pro stress-test →DBV Technologies is a French clinical-stage biopharmaceutical company pioneering epicutaneous immunotherapy (EPIT) to treat food allergies and immunological disorders. The company's flagship VIASKIN Peanut patch has completed Phase 3 trials and recently announced positive results in children aged 4-7 years, positioning it for potential market entry in a significant unmet medical need space.
Strategic Profile
Pro stress-test →DBV leverages its proprietary Viaskin technology platform that delivers allergen immunotherapy through intact skin, avoiding systemic exposure risks. The company is expanding its pipeline with Viaskin Milk (Phase 1/2 trials) and earlier-stage programs targeting RSV vaccines, celiac disease, and inflammatory bowel disease, alongside partnerships like Nestlé Health Science for diagnostic products.
Competitive Landscape
Pro stress-test →DBV competes in the food allergy immunotherapy space against oral immunotherapy leaders like Palforzia (Aimmune Therapeutics/Nestlé) and sublingual approaches. The EPIT patch technology differentiates DBV by targeting safety and compliance advantages, though market adoption depends on regulatory approval and physician/patient adoption relative to established oral desensitization protocols.
Industry Context
DBV Technologies S.A. operates in Biopharmaceuticals - Immunotherapy & Allergy Treatment.
Key facts
Founded: 2002 · Headquarters: Châtillon, France · Revenue: $4.15B